Quick Takeaways
- David R. Epstein has 8 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,460,508.
- Recent insider filing activity is available below.
Insider Trading & Ownership of David R. Epstein
- Location
- New York, NY
- Summary
- The estimated net worth of David R. Epstein is at least $1,460,508 dollars as of 18 Mar 2026. David R. Epstein is the Director of Tempus AI, Inc. and owns shares of Tempus AI, Inc. (TEM) stock worth about $1.31M. David R. Epstein is the Director of Axcella Health Inc. and owns shares of Axcella Health Inc. stock worth about $121.7K. David R. Epstein is the Director of Evelo Biosciences, Inc. and owns shares of Evelo Biosciences, Inc. stock worth about $31K.
- Signature
- /s/ Ellen Lefever, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow David R. Epstein and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Tempus AI, Inc. ($1,307,852).
- Past-year value change for that position: -$139,461.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of David R. Epstein
TEM
Forms 3/4/5
Tempus AI, Inc.
- Relationship
- Director
- Holdings value
- $1,307,852
- Past year net change
- -$139,461
- Change %
- -9.6%
- Report period
- 02 Mar 2026
AXLA
Forms 3/4/5
Axcella Health Inc.
- Relationship
- Director
- Holdings value
- $121,658
- Past year net change
- Change %
- Report period
- 19 May 2022
EVLO
Forms 3/4/5
Evelo Biosciences, Inc.
- Relationship
- Director
- Holdings value
- $30,998
- Past year net change
- Change %
- Report period
- 30 Jun 2022
AGMB
Forms 3/4/5
Agomab Therapeutics NV
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 18 Mar 2026
OHAA
Forms 3/4/5
Opy Acquisition Corp. I
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 26 Oct 2021
RUBY
Forms 3/4/5
Rubius Therapeutics, Inc.
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 12 May 2022
SGEN
Forms 3/4/5
Seagen Inc.
- Relationship
- CEO, Director
- Holdings value
- Past year net change
- Change %
- Report period
- 14 Dec 2023
SNTI
Forms 3/4/5
Senti Biosciences, Inc.
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 13 Jul 2022
Insider Transactions Reported by David R. Epstein:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.